Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press10710.17650/2222-1468-2014-0-4-17-21DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИCHEMO- AND TARGET THERAPY OF PATIENTS WITH BREAST CANCER WITH METASTATIC BRAIN LESIONSХИМИО- И ТАРГЕТНАЯ ТЕРАПИЯ БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ C МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГАNaskhletashviliD. R.НасхлеташвилиД. Р.
Russian Federation

Контакты: Давид Романович Насхлеташвили nas-david@yandex.ru

ФГБНУ «РОНЦ им. Н.Н. Блохина»; 115478, Россия, Москва, Каширское шоссе, 24

nas-david@yandex.ruGorbunovaV. A.ГорбуноваВ. А.
Russian Federation
nas-david@yandex.ruMoskvinaE. A.МосквинаЕ. А.
Russian Federation
nas-david@yandex.ruN.N. Blokhin Russian Cancer Research Center, MoscowФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва150420144417211804201518042015Copyright ©; 2014, Naskhletashvili D.R., Gorbunova V.A., Moskvina E.A.Copyright ©; 2014, Насхлеташвили Д.Р., Горбунова В.А., Москвина Е.А.2014Naskhletashvili D.R., Gorbunova V.A., Moskvina E.A.Насхлеташвили Д.Р., Горбунова В.А., Москвина Е.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/107

Results of studies performed have shown high efficiency of drug therapy for treatment of patients with breast cancer (BC) with brain metastases. The best results regarding survival rate have been achieved for treatment of BC patients with brain metastases and HER2 hyperexpression. At present, studies are performed regarding examination of new anticancer drugs and their use in combination with radiotherapy for treatment of BC patients with brain metastases. It is necessary to perform studies of efficiency of various schemes of drug therapy depending on biological properties of the primary tumor. The issue of sequence of application of drug therapy and radiotherapy for metastatic brain lesions also remains actual.

Результаты проведенных исследований показали высокую эффективность лекарственной терапии в лечении больных раком молочной железы (РМЖ) с метастазами в головном мозге. Наилучшие результаты в отношении показателей выживаемости достигнуты в лечении больных РМЖ с метастазами в головном мозге и с гиперэкспрессией HER2. В настоящее время продолжаются исследования по изучению новых противоопухолевых препаратов, а также их комбинированного применения в сочетании с лучевой терапией в лечении больных РМЖ с метастатическим поражением мозга. Необходимо проведение исследований эффективности различных схем лекарственной терапии в зависимости от биологических свойств первичной опухоли. Остается также актуальным вопрос о последовательности применения лекарственной и лучевой терапии при метастатическом поражении головного мозга.

breast cancer, brain metastases, chemotherapy, drug therapyрак молочной железы, метастазы в головном мозге, химиотерапия, лекарственная терапия1. Насхлеташвили Д. Р. Автореф. дис. … канд. мед. наук. Современные возможности консервативного лечения больных раком молочной железы и мелкоклеточным раком легкого с метастазами в головной мозг. М., 2002. 36 с. [Naskhletashvili D. R. Modern possibilities of conservative treatment of patients with breast cancer and small cell lung cancer with brain metastases. Author’s abstract of the thesis of a candidate of medical sciences. Moscow, 2002. 36 p. (In Russ.)]Насхлеташвили Д. Р. Автореф. дис. … канд. мед. наук. Современные возможности консервативного лечения больных раком молочной железы и мелкоклеточным раком легкого с метастазами в головной мозг. М., 2002. 36 с. [Naskhletashvili D. R. Modern possibilities of conservative treatment of patients with breast cancer and small cell lung cancer with brain metastases. Author’s abstract of the thesis of a candidate of medical sciences. Moscow, 2002. 36 p. (In Russ.)]2. Насхлеташвили Д. Р., Горбунова В. А., Бекяшев А. Х., Москвина Е. А. Таргетная терапия в комплексном лечении больных раком молочной железы с гиперэкспрессией Her-2 / neu и c метастатическим поражением головного мозга. Мат. Мультидисциплинарного форума по лечению рака молочной железы, Санкт-Петербург, 24–25 октября 2013 г., абстр., с. 33. [Naskhletashvili D. R., Gorbunova V. A., Bekyashev A. Kh., Moskvina E. A. Target therapy in complex treatment of patients with breast cancer with hyper expression of Her-2 / neu and brain metastases. Materials of the Multidisciplinary Forum for Treatment of Breast Cancer, St. Petersburg, October 24 to 25, 2013, abstr., p. 33. (In Russ.)]Насхлеташвили Д. Р., Горбунова В. А., Бекяшев А. Х., Москвина Е. А. Таргетная терапия в комплексном лечении больных раком молочной железы с гиперэкспрессией Her-2 / neu и c метастатическим поражением головного мозга. Мат. Мультидисциплинарного форума по лечению рака молочной железы, Санкт-Петербург, 24–25 октября 2013 г., абстр., с. 33. [Naskhletashvili D. R., Gorbunova V. A., Bekyashev A. Kh., Moskvina E. A. Target therapy in complex treatment of patients with breast cancer with hyper expression of Her-2 / neu and brain metastases. Materials of the Multidisciplinary Forum for Treatment of Breast Cancer, St. Petersburg, October 24 to 25, 2013, abstr., p. 33. (In Russ.)]3. Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А. Современные возможности таргетной терапии в лечении больных раком молочной железы с гиперэкспрессией Her-2 / neu и с метастатическим поражением головного мозга. Вопросы онкологии 2013;3(59):347–51. [Naskhletashvili D. R., Gorbunova V. A., Moskvina E. A. Modern capabilities of the target therapy in complex treatment of patients with breast cancer with hyper expression of Her-2 / neu and brain metastases. Voprosy Onkologii = Oncology Issues 2013;3(59):347–51. (In Russ.)]Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А. Современные возможности таргетной терапии в лечении больных раком молочной железы с гиперэкспрессией Her-2 / neu и с метастатическим поражением головного мозга. Вопросы онкологии 2013;3(59):347–51. [Naskhletashvili D. R., Gorbunova V. A., Moskvina E. A. Modern capabilities of the target therapy in complex treatment of patients with breast cancer with hyper expression of Her-2 / neu and brain metastases. Voprosy Onkologii = Oncology Issues 2013;3(59):347–51. (In Russ.)]4. Bendell J. C., Domchek S. M., Burstein H. J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972–7.Bendell J. C., Domchek S. M., Burstein H. J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972–7.5. Bezjak A., Adam J., Barton R. et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487–96.Bezjak A., Adam J., Barton R. et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487–96.6. Burstein H. J., Lieberman G., Slamon D. J. et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772–7.Burstein H. J., Lieberman G., Slamon D. J. et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772–7.7. Chang E. L., Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003;8(5):398–410.Chang E. L., Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003;8(5):398–410.8. Christodoulou C., Bafaloukos D., Linardou H. et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 2005;71:61–5.Christodoulou C., Bafaloukos D., Linardou H. et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 2005;71:61–5.9. Cocconi G., Lottici R., Bisagni G. et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327–34.Cocconi G., Lottici R., Bisagni G. et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327–34.10. De la Monte S. M., Hutchins G. M., Moore G. W. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984;76:11–7.De la Monte S. M., Hutchins G. M., Moore G. W. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984;76:11–7.11. Fabi A., Vidiri A., Ferretti G. et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006;24:466–8.Fabi A., Vidiri A., Ferretti G. et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006;24:466–8.12. Franciosi V., Cocconi G., Michiara M. et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599–605.Franciosi V., Cocconi G., Michiara M. et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599–605.13. Gorbounova V. A., Bychkov M. B., Michina Z. P., Naskhletashvili D. R. Tеmozolomide in patients with brain metastases. 16 International Congress of Anti-Cancer Treatment (01–04 / 02 / 2005, Paris, France). Abstract book, p. 306.Gorbounova V. A., Bychkov M. B., Michina Z. P., Naskhletashvili D. R. Tеmozolomide in patients with brain metastases. 16 International Congress of Anti-Cancer Treatment (01–04 / 02 / 2005, Paris, France). Abstract book, p. 306.14. Heinrich B., Brudler O., Siekiera W. et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003;22:37 (abstr. 147).Heinrich B., Brudler O., Siekiera W. et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003;22:37 (abstr. 147).15. Hikino H., Yamada T., Johbara K. et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006;15:97–9.Hikino H., Yamada T., Johbara K. et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006;15:97–9.16. Khuntia D., Brown P., Li J. et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24:1295–304.Khuntia D., Brown P., Li J. et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24:1295–304.17. Lin N. U., Bellon J. R., Winer E. P. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608–17.Lin N. U., Bellon J. R., Winer E. P. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608–17.18. Naskhletashvili D., Gorbounova V., Bychkov M. et al. Targeted therapy (lapatinib and / or trastuzumab) and capecitabine th in breast cancer (BC) patients with Her-2 / neu overexpression and brain metastases (BM). EORTC-EANO-ESMO conference 2013 on trends in Central Nervous System Malignancies, Prague, 22–23 March 2013, abstr. 164 (+ poster р. 164).Naskhletashvili D., Gorbounova V., Bychkov M. et al. Targeted therapy (lapatinib and / or trastuzumab) and capecitabine th in breast cancer (BC) patients with Her-2 / neu overexpression and brain metastases (BM). EORTC-EANO-ESMO conference 2013 on trends in Central Nervous System Malignancies, Prague, 22–23 March 2013, abstr. 164 (+ poster р. 164).19. Naskhletashvili D. R. Gorbunova V. A., Bychkov M. B. et al. Gemcitabine plus cisplatin in patients with heavily pretreated breast cancer with brain metastases. J Clinl Oncol 2010;28:7s (suppl; abstr. 1125).Naskhletashvili D. R. Gorbunova V. A., Bychkov M. B. et al. Gemcitabine plus cisplatin in patients with heavily pretreated breast cancer with brain metastases. J Clinl Oncol 2010;28:7s (suppl; abstr. 1125).20. Naskhletashvili D. R. Gorbunova V., Bychkov M. et al. The role of temozolomide for patients with metastatic brain disease. Abstracts from the 9 meeting of the European Association of Neuro-Oncology, Maastricht, the Netherlands, September 16–19, 2010, p. 57–58.Naskhletashvili D. R. Gorbunova V., Bychkov M. et al. The role of temozolomide for patients with metastatic brain disease. Abstracts from the 9 meeting of the European Association of Neuro-Oncology, Maastricht, the Netherlands, September 16–19, 2010, p. 57–58.21. Oberhoff C., Kieback D. G., Wurstlein R. et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24: 256–60.Oberhoff C., Kieback D. G., Wurstlein R. et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24: 256–60.22. Rosner D., Flower A., Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993;12:508a.Rosner D., Flower A., Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993;12:508a.23. Rosner D., Nemoto T., Lane W. W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832–9.Rosner D., Nemoto T., Lane W. W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832–9.24. Samaan N. A., Buzdar A. U., Aldinger K. A. et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981;47:554–60.Samaan N. A., Buzdar A. U., Aldinger K. A. et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981;47:554–60.25. Siegelmann-Danieli N., Stein M., Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003;5:833–4.Siegelmann-Danieli N., Stein M., Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003;5:833–4.26. Tsao M. N., Lloyd N., Wong R. et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869.Tsao M. N., Lloyd N., Wong R. et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869.27. Wang M. L., Yung W. K., Royce M. E. et al. Capecitabine for 5-fluorouracilresistant brain metastases from breast cancer. Am J Clin Oncol 2001;24:421–4.Wang M. L., Yung W. K., Royce M. E. et al. Capecitabine for 5-fluorouracilresistant brain metastases from breast cancer. Am J Clin Oncol 2001;24:421–4.28. Wardley A. M., Danson S., Clayton A. J. et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 2002;21:61a (abstr. 241).Wardley A. M., Danson S., Clayton A. J. et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 2002;21:61a (abstr. 241).29. Weitzen R., Zach L., Kaufman B. et al. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:316 (abstr. 1936).Weitzen R., Zach L., Kaufman B. et al. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:316 (abstr. 1936).